A nonrandomized phase II trial of sorafenib (S) and everolimus (E) in unresectable metastatic osteosarcoma (OST) patients (pts) relapsed after standard chemotherapy

Authors :: Virginia Ferraresi
Stefano Ferrari
Giovanni Grignani
Lorenzo D'Ambrosio
Emanuela Marchesi
Roberto Biagini
Angela Tamburini
Piero Picci
Massimo Aglietta
Franca Fagioli
Marco Gambarotti
Emanuela Palmerini
Rossella Bertulli
Annamaria Nuzzo
Ymera Pignochino
Sebastian Dorin Asaftei
Paolo G. Casali
Giovanni Grignani
Emanuela Palmerini
Virginia Ferraresi
Sebastian Dorin Asaftei
Lorenzo D'Ambrosio
Ymera Pignochino
Annamaria Nuzzo
Marco Gambarotti
Emanuela Marchesi
Roberto Biagini
Angela Tamburini
Rossella Bertulli
Paolo G Casali
Franca Fagioli
Piero Picci
Stefano Ferrari
Massimo Aglietta
Source :: Alma Mater Studiorum Università di Bologna-IRIS
Abstract: 10533^ Background: After standard therapy OST relapse is an ominous event almost uniformly fatal in non resectable cases. Our group explored the activity of the multikinase inhibitor S demonstratin...

Subjects :: Sorafenib
Oncology
Cancer Research
medicine.medical_specialty
Chemotherapy
Everolimus
business.industry
medicine.medical_treatment
fungi
Multikinase inhibitor
metastatic osteosarcoma
Internal medicine
Metastatic osteosarcoma
medicine
business
Standard therapy
medicine.drug

Tools